Targeting Ligands Deliver Model Drug Cargo into the Central Nervous System along Autonomic Neurons

By Drew L. Sellers, James-Kevin Y. Tan, Julio Marco B. Pineda, David J. Peeler, Veronica L. Porubsky, Brynn R. Olden, Stephen J. Salipante, Suzie H. Pun

March 24, 2020

  • Year

  • Technique

  • Industry

Title

Targeting Ligands Deliver Model Drug Cargo into the Central Nervous System along Autonomic Neurons

Author

Drew L. Sellers, James-Kevin Y. Tan, Julio Marco B. Pineda, David J. Peeler, Veronica L. Porubsky, Brynn R. Olden, Stephen J. Salipante, Suzie H. Pun

Year

2019

Journal

ACS Nano

Abstract

While biologic drugs such as proteins, peptides, or nucleic acids have shown promise in the treatment of neurodegenerative diseases, the blood–brain barrier (BBB) severely limits drug delivery to the central nervous system (CNS) after systemic administration. Consequently, drug delivery challenges preclude biological drug candidates from the clinical armamentarium. In order to target drug delivery and uptake into to the CNS, we used an in vivo phage display screen to identify peptides able to target drug-uptake by the vast array of neurons of the autonomic nervous system (ANS). Using next-generation sequencing, we identified 21 candidate targeted ANS-to-CNS uptake ligands (TACL) that enriched bacteriophage accumulation and delivered protein-cargo into the CNS after intraperitoneal (IP) administration. The series of TACL peptides were synthesized and tested for their ability to deliver a model enzyme (NeutrAvidin-horseradish peroxidase fusion) to the brain and spinal cord. Three TACL-peptides facilitated significant active enzyme delivery into the CNS, with limited accumulation in off-target organs. Peptide structure and serum stability is increased when internal cysteine residues are cyclized by perfluoroarylation with decafluorobiphenyl, which increased delivery to the CNS further. TACL-peptide was demonstrated to localize in parasympathetic ganglia neurons in addition to neuronal structures in the hindbrain and spinal cord. By targeting uptake into ANS neurons, we demonstrate the potential for TACL-peptides to bypass the blood–brain barrier and deliver a model drug into the brain and spinal cord.

Full Article

https://pubs.acs.org/doi/abs/10.1021/acsnano.9b01515

Instrument

J-720

Keywords

Circular dichroism, Secondary structure, Chemical stability, Protein stability, Biochemistry